abrdn Life Sciences Investors (HQL) is the subject of a joint ownership report by First Trust Portfolios L.P., First Trust Advisors L.P. and The Charger Corporation. Each reports beneficial ownership of 3,551,582 shares, or 11.34% of the class, and each disclaims beneficial ownership of the shares identified. First Trust Portfolios reports 3,478,170 shares held by unit investment trusts it sponsors. First Trust Advisors and The Charger Corporation each report shared voting power over 73,412 shares; the reporting persons state that the trustees vote the shares held by those trusts.
abrdn Life Sciences Investors director Chris LaVictoire Mahai purchased 527 shares of Common Stock on 2026-07-16 in an open-market or private transaction at $19.92 per share. After this trade, Mahai directly owns 527 shares of HQL. The filing indicates the transaction was not under a Rule 10b5-1 trading plan.
abrdn Life Sciences Investors director Mahai Chris LaVictoire has filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. The filing shows no reportable transactions or holdings, indicating no beneficial ownership entries at the time of this report.
abrdn Life Sciences Investors disclosure: a Schedule 13G/A shows First Trust Portfolios L.P., First Trust Advisors L.P. and The Charger Corporation jointly report beneficial ownership of 3,021,786 shares of Common stock, representing 10.09% as of 02/28/2026.
The filing states the three entities are filing jointly under Rule 13d-1(k)(1), describes relationships among the entities, and includes disclaimers that they disclaim beneficial ownership of the shares held in certain unit investment trusts and advisory accounts.
Saba Capital Management and related parties filed Amendment No. 12 to their Schedule 13D on abrdn Life Sciences Investors, updating their disclosure of a significant position in the fund’s common shares.
The reporting group now reports beneficial ownership of 1,464,161 common shares, representing 4.95% of the outstanding shares based on 29,598,692 shares outstanding as of September 30, 2025. The filing states that approximately $19,201,394 was paid in total to acquire these shares, with purchases funded by investor capital, related appreciation, and ordinary-course margin borrowings.
Recent activity consisted of open-market transactions between February 11, 2026 and February 19, 2026, as detailed in Schedule A to the amendment. The filers indicate no specific corporate action or change of control purpose for the investment and report no special contracts or arrangements regarding the issuer’s securities.
Saba Capital Management and related reporting persons disclose a 5.7% beneficial ownership stake in abrdn Life Sciences Investors. They report holding 1,686,997 common shares, calculated against 29,598,692 shares outstanding as of 9/30/25. The filing is Amendment No. 11 to their Schedule 13D.
Funds used to purchase these shares came from investor subscription proceeds, capital appreciation and ordinary-course margin borrowings, with approximately $22,123,724 paid in total. Voting and dispositive power over the shares is shared among Saba Capital, Saba Capital Management GP, LLC and Boaz R. Weinstein, with no sole voting or dispositive power reported.
Saba Capital Management and affiliates report a significant position in abrdn Life Sciences Investors. In this Amendment No. 10, Saba Capital Management, L.P., Saba Capital Management GP, LLC, and Boaz R. Weinstein disclose beneficial ownership of 2,002,516 common shares of abrdn Life Sciences Investors, representing 6.77% of the outstanding shares, based on 29,598,692 shares outstanding as of 9/30/25.
The reporting persons have shared voting and dispositive power over 2,002,516 shares and no sole voting or dispositive power. They state that approximately $26,261,523 was paid to acquire the common shares, using investor subscription proceeds, capital appreciation, and margin borrowings in the ordinary course of business, with positions in margin accounts pledged as collateral.
All reported trades between 11/24/25 and 1/7/26 were executed in the open market, as detailed in Schedule A. Dividends and sale proceeds from these shares are payable to the funds and accounts advised by Saba Capital.
abrdn Life Sciences Investors filed an initial insider ownership report for a vice president of abrdn. The filing, dated 12/09/2025 as the event date, identifies the individual as an officer of the fund. The report states in the remarks that no securities are beneficially owned by the reporting person. This Form 3 establishes the officer’s ownership status for regulatory disclosure purposes.
abrdn Life Sciences Investors reported that one of its directors acquired 7,923 shares of its common stock on 12/16/2025 at a price of $16.8818 per share. Following this transaction, the director directly beneficially owned 7,923 shares of the company.
Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein filed Amendment No. 9 to Schedule 13D reporting beneficial ownership of 2,274,356 common shares of abrdn Life Sciences Investors (HQL), equal to 7.88% of the outstanding shares based on 28,872,416 shares outstanding as of 3/31/25. The event triggering this filing occurred on 11/21/2025.
All reporting persons share voting and dispositive power over these shares and have no sole voting or dispositive authority. Approximately $29,826,505 was paid to acquire the reported position, using investor subscription proceeds, capital appreciation, and ordinary-course margin borrowings. Funds and accounts advised by Saba Capital are entitled to dividends and sale proceeds. This amendment updates Items 3, 5 and 7, and lists Schedule A as an exhibit detailing recent open-market transactions.